Sales of Amylyx’s ALS drug, Relyvrio, beat fourth-quarter expectations on Thursday, and AMLX stock bounded well above its 50-day line.
The post Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter appeared first on Investor’s Business Daily.